Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 6/20 | 0.50 |
| ▸ | CMA1 | P23946 | 9/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.44 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404207 | 0.94 | CMA1 (0.48) | PRSS12CMA1TRPC3TRPC6PRSS1 | |
| SCHEMBL998620 | 0.92 | PRSS12 (0.48) | PRSS12CMA1MCHR1PRSS1PRSS2 | |
| SCHEMBL10260371 | 0.85 | PRSS12 (0.43) | PRSS12CMA1TRPC3TRPC6 | |
| SCHEMBL4132747 | 0.84 | PRSS12 (0.47) | PRSS12TRPC3TRPC6MCHR1HSD11B1 | |
| SCHEMBL998624 | 0.81 | CMA1 (0.46) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999165 | 0.78 | CMA1 (0.60) | CMA1NPC1RAB9APRSS1PRSS2 | |
| SCHEMBL4139599 | 0.76 | PRSS12 (0.45) | PRSS12CMA1MCHR1NPC1 | |
| SCHEMBL1000593 | 0.74 | CMA1 (0.54) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL13952745 | 0.70 | CMA1 (0.42) | CMA1TRPC3TRPC6NPC1RAB9A | |
| SCHEMBL3220314 | 0.69 | PRSS12 (0.49) | PRSS12TRPC3TRPC6HSD11B1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | PRSS12 563/4885CMA1 1/4885TRPC3 4652/4885 |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | CMA1, PPA1, CPN1 | PRSS12 563/4885CMA1 1/4885TRPC3 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.